Skip to main content

22-07-2017 | Lymphoma | Article

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

Current Hematologic Malignancy Reports

Authors: Thomas U. Marron, Matko Kalac, Joshua Brody

Publisher: Springer US


Purpose of Review

Throughout the field of oncology, immunotherapy is moving further towards the first-line setting, and there is encouraging data for the use of these novel therapies in the management of lymphomas, utilizing treatments approved for both solid and hematologic malignancies. Herein, we review promising advances in this rapidly moving field from the past year.

Recent Findings

In the last year, we have seen promising clinical data on engineered antibody therapies for the treatment of lymphomas, as well as further optimization of engineered antibody fragments fused onto linkers or chimeric T cell receptors, both of the modalities capable of transforming non-specific T cells into tumor-specific, serial killer cells.


Here we will review the promising data on these advances in antibody-based therapies, as well as some of the immunomodulators and checkpoint-blocking therapies that shown to have promising results in the treatment of lymphomas within the past year.

Please log in to get access to this content

Related topics

Image Credits